Abstract

Estriol: Women's Choice vs. A Manufacturer's Greed

Author(s): Goodrum Jennifer

Issue: Jul/Aug 2008 - Hormone Replacement Therapy

Page(s): 286-292

Download in electronic PDF format for $75

Abstract

The U.S. Food and Drug Administration recently took action to†hal4 the compounding of hormone preparations that contain estriol, an action requested in a citizen petition filed by Wyeth Pharmaceuticals. If the Food and Drug Administration, with the support of Wyeth, is successful in its efforts, women throughout the U.S. who rely on compounded hormones containing estriol will have to discontinue their prescribed treatment. The International Academy of Compounding Pharmacists is engaged in ongoing outreach to ensure that members of Congress recognize the importance of protecting pharmacy compounding for the health and well-being of their constituents. Significant progress has been made with the recent introduction of a congressional resolution in support of estriol.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2008 Pg. 286-292	Estriol: Women's Choice vs. A Manufacturer's Greed Author(s): Goodrum Jennifer
Jul/Aug 2003 Pg. 250-256	A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 1 Author(s): Gillson George R, Zava David T
Sep/Oct 2016 Pg. 359-364	Menopausal Symptom Relief and Side Effects Experienced by Women Using Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 1 Author(s): Deleruyelle Laura J
Nov/Dec 2016 Pg. 447-454	Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 2 Author(s): Deleruyelle Laura J
Mar/Apr 2010 Pg. 165-170	Menopausal Women's Access Path to Bioidentical Hormone Replacement Therapy: An Exploratory Study Author(s): Moro Doris, Young Wendy, Stein Richard, Isaac Winston, Goodman Deborah
Jul/Aug 2004 Pg. 313-319	Efficacy and Tolerability of Compounded Bioidentical Hormone Replacement Therapy Author(s): Vigesaa Kristy A, Downhour Nathan P, Chui Michelle A, Cappellini Linda, Musil John D, McCallian Dennis J
Jul/Aug 2016 Pg. 351 View Sample	Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines Author(s): Allen Loyd V Jr
Sep/Oct 2017 Pg. 356	PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs Author(s): Allen Loyd V Jr
Jan/Feb 2017 Pg. 6-16	Menopausal Symptom Relief and Side Effects Experienced by Women Using Compounded Bioidentical Hormone Replacement Therapy and Synthetic Conjugated Equine Estrogen and/or Progestin Hormone Replacement Therapy, Part 3 Author(s): Deleruyelle Laura J
Jan/Feb 2023 Pg. 22-23	The U.S. Food and Drug Administration Takes Aim at Compounded Thyroid Hormone Author(s): Brunner Scott
Jan/Feb 2001 Pg. 52-54	Using Serum Hormone Analysis to Develop Hormone Replacement Therapy Regimens - Part 2 Author(s): Ford Gina, Garcia Lea
Jan/Feb 2013 Pg. 74-85 View Sample	The Effects of Compounded Bioidentical Transdermal Hormone Therapy on Hemostatic, Inflammatory, and Immune Factors; Cardiovascular Biomarkers; Quality of Life Measures; and Health Outcomes in Perimenopausal and Postmenopausal Women Author(s): Stephenson Kenna, Neuenschwander Pierre F, Kurdowska Anna K
Jul/Aug 2008 Pg. 284	PreScription: First Estriol, Then What? Author(s): Allen Loyd V Jr
Sep/Oct 2003 Pg. 330-338	A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Author(s): Gillson George R, Zava David T
May/Jun 2006 Pg. 175-183	The Role of Drug Promotion in the Prescription of Hormone Replacement Therapy in the United States Author(s): Stephenson Kenna, Jones William, Stephenson Douglas M M
Jul/Aug 2015 Pg. 303-305	U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances Author(s): Miller David G
May/Jun 2018 Pg. 190-195	Establishing a Rationale for Compounding Hormone Replacement Therapy Author(s): Biundo Bruce
Jan/Feb 2024 Pg. 22-27	Establishing a Rationale for Compounding Hormone Replacement Therapy Author(s): Biundo Bruce
Jul/Aug 2007 Pg. 278-281	The Politics of Hormone Replacement Therapy Author(s): Allen Loyd V Jr
Jan/Feb 2002 Pg. 50-54	Bioidentical Hormone Replacement Therapy, Part 2, A Review of Author(s): Wepfer Scott T